Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kiem Liem

Hematology & Oncology Long Beach, CA Medical Doctor

NPI 1407875982 CMS profile 63896

3747 Worsham Ave Ste 101, Long Beach, CA 90808

Open in the dashboard

General payments

$9,061

407 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$37,636 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Kiem Liem of Long Beach, CA is reported in the CMS Open Payments database as having received $9,061 across 407 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,636 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 69th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $21 1
2022 General $193 12
2021 General $2,665 71
2020 General $2,507 132
2019 General $3,674 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kiem Liem
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Kiem Liem were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Kiem Liem Hematology & Oncology median Middle half National median
2019 $3,674 $529 $121–$2,516 $163
2020 $2,507 $339 $82–$2,213 $114
2021 $2,665 $263 $49–$1,965 $132
2022 $193 $416 $103–$2,395 $149
2023 $21 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,390 7 payments
  2. Amgen Inc. $800 40 payments
  3. Pfizer Inc. $781 60 payments
  4. Genentech USA, Inc. $466 22 payments
  5. Janssen Biotech, Inc. $388 15 payments
  6. Merck Sharp & Dohme Corporation $367 20 payments
  7. Lilly USA, LLC $348 15 payments
  8. Puma Biotechnology, Inc. $320 14 payments
  9. Daiichi Sankyo Inc. $311 21 payments
  10. Incyte Corporation $298 14 payments
  11. Other $3,592 179 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,019 371 payments
  2. Consulting Fee $1,100 1 payment
  3. Education $942 35 payments
Products named General payments · program years 2019–2023
  1. KEYTRUDA $340 18 payments
  2. CYRAMZA $326 14 payments
  3. TECENTRIQ $323 13 payments
  4. NERLYNX $320 14 payments
  5. JAKAFI $298 14 payments
  6. VERZENIO $294 12 payments
  7. Vectibix $294 14 payments
  8. XGEVA $277 14 payments
  9. ZEJULA $276 10 payments
  10. INLYTA $274 20 payments
  11. Other $7,315 404 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$22,980

Medicare's payments for the services billed

Medicare patients

147

Average age 74

Services billed

409

62 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Cancer 46%
Arthritis 39%
Ischemic heart disease 31%
COPD 23%
Atrial fibrillation 21%
Diabetes 20%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

407 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record